Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CHKA | P35790 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.34 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25290210 | 0.97 | CA2 (0.36) | CA2CA12CA1CA9CHKA | |
| SCHEMBL29532005 | 0.97 | CA2 (0.36) | CA2CA12CA1CA9CHKA | |
| Hydrochloric Acid SCHEMBL28543928 | 0.97 | CA2 (0.36) | CA2CA12CA1CA9CHKA | |
| SCHEMBL31197556 | 0.97 | CA2 (0.36) | CA2CA12CA1CA9CHKA | |
| SCHEMBL1565193 | 0.84 | — | — | |
| SCHEMBL29135811 | 0.81 | CA2 (0.36) | CA2CA12CA1CA9CHKA | |
| SCHEMBL15536892 | 0.78 | FDPS (0.33) | CA2 | |
| SCHEMBL3392230 | 0.78 | FDPS (0.33) | CA2 | |
| SCHEMBL8862365 | 0.77 | CA2 (0.35) | CA2CA12CA1CA9CHKA | |
| Phosphoric Acid SCHEMBL29046939 | 0.74 | CA2 (0.39) | CA2CA12CA1CA9CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113329739-B | Antisense oligonucleotides targeted to SCN2A for the treatment of SCN1A encephalopathy | 罗贡股份有限公司 | 2024-06-25 | — | — | CN | claimed |
| US-11939582-B2 | Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies | ROGCON, INC. (US) | 2024-03-26 | — | — | US | claimed |
| US-20240076670-A1 | ANTISENSE POLYNUCLEOTIDES TO INDUCE EXON SKIPPING AND METHOD OF TREATING DYSTROPHIES | UNIV CHICAGO (US) | 2024-03-07 | — | — | US | claimed |
| EP-4320237-A1 | OLIGONUCLEOTIDES | Hudson Institute of Medical Research (AU) | 2024-02-14 | — | — | EP | claimed |
| US-20230348903-A1 | OLIGONUCLEOTIDES | Hudson Institute of Medical Research (AU) | 2023-11-02 | — | — | US | claimed |
| WO-2023192885-A2 | METHODS OF USING OLIGOMERIC COMPOUNDS TO TREAT SCN2A-RELATED DISORDERS | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-10-05 | — | — | WO | claimed |
| WO-2023150716-A2 | METHODS FOR THE TREATMENT OF SCN2A-RELATED DISORDERS | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-08-10 | — | — | WO | claimed |
| US-20230183700-A1 | ANTISENSE POLYNUCLEOTIDES TO INDUCE EXON SKIPPING AND METHOD OF TREATING DYSTROPHIES | UNIV CHICAGO (US) | 2023-06-15 | — | — | US | claimed |
| US-20230167452-A1 | COMPOSITIONS AND METHODS FOR CORRECTING LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2C USING EXON SKIPPING | UNIV CHICAGO (US) | 2023-06-01 | — | — | US | claimed |
| US-20230104708-A1 | EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | US | claimed |
| EP-0515511-B1 | METHOD OF SITE-SPECIFIC ALTERATION OF RNA AND PRODUCTION OF ENCODED POLYPEPTIDES | WORCESTER FOUND EX BIOLOGY (US) | 1996-08-14 | — | — | EP | claimed |
| EP-0698092-A1 | ANTISENSE OLIGONUCLEOTIDES WHICH COMBAT ABERRANT SPLICING AND METHODS OF USING THE SAME | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1996-02-28 | — | — | EP | claimed |
| EP-0402402-B1 | INHIBITION OF HTLV-III BY EXOGENOUS OLIGONUCLEOTIDES | WORCESTER FOUND EX BIOLOGY (US) | 1995-12-27 | — | — | EP | claimed |
| WO-1994026887-A1 | ANTISENSE OLIGONUCLEOTIDES WHICH COMBAT ABERRANT SPLICING AND METHODS OF USING THE SAME | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1994-11-24 | — | — | WO | claimed |
| US-5366878-A | Removal and replacement of selected nucleotides in RNA | THE WORCESTER FOUNDATION FOR EXPERIMENTAL BIOLOGY (US) | 1994-11-22 | — | — | US | claimed |
| US-5149797-A | METHOD OF SITE-SPECIFIC ALTERATION OF RNA AND PRODUCTION OF ENCODED POLYPEPTIDES | THE WORCESTER FOUNDATION FOR EXPERIMENTAL BIOLOGY (US) | 1992-09-22 | — | — | US | claimed |
| WO-1991012323-A1 | METHOD OF SITE-SPECIFIC ALTERATION OF RNA AND PRODUCTION OF ENCODED POLYPEPTIDES | WORCESTER FOUNDATION FOR EXPERIMENTAL BIOLOGY (US) | 1991-08-22 | — | — | WO | claimed |
| WO-1989008146-A1 | INHIBITION OF HTLV-III BY EXOGENOUS OLIGONUCLEOTIDES | WORCESTER FOUNDATION FOR EXPERIMENTAL BIOLOGY (US) | 1989-09-08 | — | — | WO | claimed |
| US-4540508-A | PIPERAZINE DERIVATIVES | THE DOW CHEMICAL COMPANY (US) | 1985-09-10 | — | — | US | claimed |
| US-3954761-A | SCALE AND CORROSION INHIBITORS | PETROLITE CORPORATION (US) | 1976-05-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939582-B2 | Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies | SCN1A, SCN2A, SCN1B | CA2 1254/4885CA12 3949/4885CA1 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.